Skip to main content

Coronavirus Disease 2019

2
Pipeline Programs
7
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

SyneuRx
SyneuRxTaiwan - Taipei
1 program
1
Pentarlandir™ UPPTAPhase 21 trial
Active Trials
NCT04911777Unknown90Est. Mar 2022
Ophirex
OphirexCA - San Francisco
1 program
1
VarespladibPhase 21 trial
Active Trials
NCT04969991Terminated18Est. Nov 2022
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
COVID-19 Associated Lymphopenia Pathogenesis Study in BloodN/A1 trial
Active Trials
NCT04401436Completed240Est. Feb 2025
Hua Medicine
Hua MedicineChina - Shanghai
1 program
Neurologic Manifestations of COVID-19N/A
Avenue Therapeutics
Avenue TherapeuticsFL - Bay Harbor Islands
1 program
Neurologic Manifestations of COVID-19N/A1 trial
Active Trials
NCT04386083Unknown1,342Est. Mar 2021
Verona Pharma
Verona PharmaUK - London
1 program
not applicableN/A1 trial
Active Trials
NCT04497194Completed430Est. Sep 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SyneuRxPentarlandir™ UPPTA
OphirexVarespladib
Avenue TherapeuticsNeurologic Manifestations of COVID-19
Allergy TherapeuticsCOVID-19 Associated Lymphopenia Pathogenesis Study in Blood
Verona Pharmanot applicable

Clinical Trials (5)

Total enrollment: 2,120 patients across 5 trials

NCT04911777SyneuRxPentarlandir™ UPPTA

Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19

Start: Aug 2021Est. completion: Mar 202290 patients
Phase 2Unknown
NCT04969991OphirexVarespladib

Study of Varespladib in Patients Hospitalized With Severe COVID-19

Start: Jun 2021Est. completion: Nov 202218 patients
Phase 2Terminated
NCT04386083Avenue TherapeuticsNeurologic Manifestations of COVID-19

Neurologic Manifestations of COVID-19

Start: Jun 2020Est. completion: Mar 20211,342 patients
N/AUnknown
NCT04401436Allergy TherapeuticsCOVID-19 Associated Lymphopenia Pathogenesis Study in Blood

COVID-19 Associated Lymphopenia Pathogenesis Study in Blood

Start: May 2020Est. completion: Feb 2025240 patients
N/ACompleted
NCT04497194Verona Pharmanot applicable

Registry of COVID-19 Patients at AOUI Verona

Start: Mar 2020Est. completion: Sep 2020430 patients
N/ACompleted

Related Jobs

Sr Director, Finance - FP & A

Gilead SciencesGilead Sciences
United States - California - Foster City (Onsite Required)
Yesterday
$243K - $315K/yr

Sr. Prevention Specialist, HIV Prevention -- Chicago Downtown South

Gilead SciencesGilead Sciences
United States - Field (Field-Based)
Yesterday
$133K - $172K/yr

Associate Scientist, FPD

Gilead SciencesGilead Sciences
United States - California - Foster City (Onsite Required)
Yesterday
$110K - $142K/yr

Senior Manager, Commercial Analytics - HIV Prevention Integrated Insights

Gilead SciencesGilead Sciences
United States - California - Foster City (Onsite Required)
Yesterday
$169K - $219K/yr

Manager, U.S. Medical Affairs Liver Strategy

Gilead SciencesGilead Sciences
United States - California - Foster City (Onsite - Hybrid Eligible)
Yesterday
$147K - $190K/yr

Sr Scientist, Drug Metabolism

Gilead SciencesGilead Sciences
United States - California - Foster City (Onsite Required)
Yesterday
$169K - $219K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.